Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Declines By 25.0%

Biofrontera Inc. (NASDAQ:BFRI) was the target of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 165,500 shares, a decrease of 25.0% from the January 31st total of 220,600 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily volume of 800,200 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Trading of Biofrontera

A number of institutional investors and hedge funds have recently bought and sold shares of BFRI. Rosalind Advisors Inc. grew its holdings in shares of Biofrontera by 63.9% in the fourth quarter. Rosalind Advisors Inc. now owns 811,918 shares of the company’s stock valued at $885,000 after purchasing an additional 316,428 shares in the last quarter. AIGH Capital Management LLC increased its holdings in shares of Biofrontera by 61.8% in the 4th quarter. AIGH Capital Management LLC now owns 811,097 shares of the company’s stock valued at $884,000 after acquiring an additional 309,663 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Biofrontera in the fourth quarter valued at $48,000. 10.08% of the stock is currently owned by hedge funds and other institutional investors.

Biofrontera Price Performance

Shares of BFRI stock traded down $0.04 on Tuesday, hitting $0.83. The stock had a trading volume of 44,260 shares, compared to its average volume of 921,577. The company’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.05. Biofrontera has a 1 year low of $0.65 and a 1 year high of $2.43. The firm has a market capitalization of $6.41 million, a P/E ratio of -0.37 and a beta of 0.29.

Wall Street Analysts Forecast Growth

Separately, Benchmark reaffirmed a “buy” rating and set a $7.00 target price on shares of Biofrontera in a research note on Friday, November 15th.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.